Stock listing
OTC:VRPX Virpax Pharmaceuticals, Inc. Stock
Follow Virpax Pharmaceuticals, Inc. into a list and get an email when it puts out news.
Share price · OTC:VRPX
$0.0020 USD 0.0000 (0.0%)
Close on Nov 12, 2026
- Day range
- $0.0020 – $0.0020 USDNov 12, 2026
- Market cap
- $2,485 USDAt the close on Nov 12, 2026 · price × 1.24M shares outstanding
- Traded on an average day
- $0 USDMedian day 0 shares · 17 days with no trades · last 3 months, Oct 8, 2026 – Nov 12, 2026

Daily closes
Last 3 months, Oct 8, 2026 – Nov 12, 2026 · OTC:VRPX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.0020 | 0.0000 | 0.0% | $0.0020 | $0.0020 | $0.0020 | 0 | |
| $0.0020 | +0.0004 | +25.0% | $0.0020 | $0.0020 | $0.0020 | 356 | |
| $0.0016 | +0.0006 | +60.0% | $0.0016 | $0.0016 | $0.0016 | 303 | |
| $0.0010 | -0.0010 | -50.0% | $0.0010 | $0.0010 | $0.0010 | 212 | |
| $0.0020 | 0.0000 | 0.0% | $0.0020 | $0.0020 | $0.0020 | 0 | |
| $0.0020 | +0.0017 | +566.7% | $0.0020 | $0.0020 | $0.0020 | 800 | |
| $0.0003 | 0.0000 | 0.0% | $0.0003 | $0.0003 | $0.0003 | 0 | |
| $0.0003 | 0.0000 | 0.0% | $0.0003 | $0.0003 | $0.0003 | 687 | |
| $0.0003 | -0.0005 | -62.5% | $0.0003 | $0.0003 | $0.0003 | 113 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 5,127 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | +0.0006 | +300.0% | $0.0008 | $0.0008 | $0.0008 | 287 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 0 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 0 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 0 | |
| $0.0002 | — | — | $0.0002 | $0.0306 | $0.0002 | 802 |
Splits
2 splits since 2024 · OTC:VRPX · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-25 | Consolidation | |
| 1-for-10 | Consolidation |
- Ticker
- OTC:VRPX
- Asset type
- Stock
- Exchange
- OTC
- Currency
- USD
Virpax Pharmaceuticals, Inc. on 6ix
- Decks
- 2 decks · latest Sep 10, 2021
Valuation
price Nov 12, 2026
- Enterprise value
- No statements on 6ix yet
- P/E
- No statements on 6ix yet
- EV/sales
- No statements on 6ix yet
- EV/EBITDA
- No statements on 6ix yet
- Price/book
- No statements on 6ix yet
- Gross margin
- No statements on 6ix yet
- Operating margin
- No statements on 6ix yet
- Net margin
- No statements on 6ix yet
- Debt to equity
- No statements on 6ix yet
- Beta vs S&P 500
- 1.26
Events
| Quarter | Results |
|---|---|
| Q4 2024 | Mar 3, 2025 · After close |
| Q3 2024 | Nov 14, 2024 · After close |
| Q2 2024 | Aug 12, 2024 · After close |
| Q1 2024 | May 13, 2024 · After close |
| Q4 2023 | Mar 26, 2024 · Before open |
| Q3 2023 | Nov 15, 2023 · After close |
| Q2 2023 | Aug 14, 2023 · Before open |
| Q1 2023 | May 12, 2023 · After close |
| Q4 2022 | Mar 22, 2023 · Before open |
| Q3 2022 | Nov 9, 2022 · After close |
All 17 quarters
| Quarter | Results |
|---|---|
| Q2 2022 | Aug 15, 2022 · After close |
| Q1 2022 | May 16, 2022 · After close |
| Q4 2021 | Mar 31, 2022 · After close |
| Q3 2021 | Dec 1, 2021 |
| Q2 2021 | Aug 10, 2021 |
| Q1 2021 | May 17, 2021 |
| Q4 2020 | Mar 31, 2021 |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| IPO Roadshow (September 2021) | IPO roadshow | 31 slides | Sep 10, 2021 |
| IPO Roadshow (January 2021) | IPO roadshow | 29 slides | Jan 8, 2021 |
Financials
Annual, in USD
Income statement
| Line | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Research and development | 5.82M | 5.12M | 10.8M | 4.84M | 1.29M | 622.7K | 1.14M |
| Selling, general and administrative | 6.26M | 7.82M | 11.1M | 7.19M | 2.90M | 2.56M | 1.48M |
| Operating income | -12.1M | -12.9M | -21.8M | -12.0M | -4.20M | -3.18M | -2.63M |
| Depreciation and amortization | 12.9M | 12.9M | 18.3M | 12.0M | 4.20M | 3.18M | 2.63M |
| EBITDA | 859.9K | 0 | -3.50M | 0 | 0 | 0 | 0 |
| Interest expense | 103.8K | 194.4K | 92.8K | 147.9K | 124.6K | 15.0K | |
| Income before tax | -12.1M | -15.2M | -21.7M | -12.1M | -4.34M | -3.31M | -2.64M |
| Income tax | -12.9K | -194.4K | 92.8K | 147.9K | 124.6K | -161.1K | |
| Net income | -12.1M | -15.2M | -21.5M | -12.1M | -4.49M | -3.43M | -2.64M |
| Earnings per share, basic | -2.84 | -12.97 | -18.32 | -10.37 | -9.07 | -6.58 | -0.53 |
Balance sheet
| Line | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 1.51M | 9.14M | 19.0M | 36.8M | 54.8K | 41.5K | 48.4K |
| Short-term investments | 1.51B | ||||||
| Receivables | 0 | 1.39K | 0 | ||||
| Inventory | 3.33K | ||||||
| Current assets | 1.56M | 9.63M | 19.7M | 39.6M | 73.1K | 46.7K | 61.5K |
| Total assets | 1.56M | 9.63M | 19.7M | 39.6M | 465.4K | 46.7K | 61.5K |
| Accounts payable | 18.5K | 18 | 37.6K | 19.8K | 22.1K | 3.50K | 6.55K |
| Current liabilities | 2.47M | 7.69M | 3.09M | 2.09M | 3.66M | 2.78M | 1.25M |
| Long-term debt | 1.02M | ||||||
| Total debt | 1.57M | 1.26M | 500.0K | ||||
| Total liabilities | 2.47M | 7.69M | 3.09M | 2.09M | 4.68M | 2.78M | 1.25M |
| Shareholders' equity | -913.8K | 1.93M | 16.6M | 37.5M | -4.22M | -2.73M | -1.19M |
| Shares outstanding | 4.25M | 1.17M | 1.17M | 1.17M | 494.5K | 521.5K | 4.95M |
Cash flow
| Line | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -16.7B | -9.85M | -17.8M | -14.5M | -1.38M | -1.13M | -1.80M |
| Capital spending | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | -16.7B | -9.85M | -17.8M | -14.5M | -1.38M | -1.13M | -1.80M |
| Cash from financing | 9.08B | 0 | 50.9K | 51.3M | 1.40M | 1.13M | 1.67M |
| Change in cash | -7.63B | -9.85M | -17.8M | 36.8M | 13.3K | -6.83K | -124.9K |
Cap table
Built by 6ix from Virpax Pharmaceuticals, Inc.’s releases
- Common shares
- 1,242,504
- Fully diluted
- 1,242,504
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 1,242,504 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 1,242,504 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Gary Jacob Other companies: OKYO Pharma Limited (Chief Development Officer/Director · Since at least May 16, 2022); Hepion Pharmaceuticals, Inc. (Director · Oct 7, 2013 – Feb 19, 2024 · Past); Callisto Pharmaceuticals Inc (Chief Executive Officer, Director · Jan 17, 2013 – Jan 17, 2013 · Past); Cardiff Oncology, Inc. (Director · Jan 23, 2012 – Mar 23, 2021 · Past); Synergy Pharmaceuticals Inc (Executive Chairman, Director · Dec 6, 2011 – Jun 15, 2018 · Past) | Director · Feb 16, 2021 – Jan 1, 2022 · Past |
| Gary L Herman Other companies: Trxade Group Inc (Director · Since at least Feb 4, 2026); Tron Inc. (Director · Since at least Aug 14, 2023); LQR House Inc. (Director · Aug 9, 2023 – Aug 9, 2023 · Past); DriveItAway Holdings Inc. (Director · Jul 6, 2017 – Jul 6, 2017 · Past) | Director · Jul 5, 2024 – Jul 5, 2024 · Past |
| Vinay Shah Other companies: Azora Therapeutics, Inc. (Chief Financial Officer · Since at least Nov 16, 2024); Adial Pharmaceuticals, Inc (Chief Financial Officer · Since at least Nov 5, 2024); Aravive Inc (Chief Financial Officer · Oct 12, 2018 – Jan 24, 2022 · Past) | Chief Financial Officer · Jun 20, 2023 – Jan 29, 2024 · Past |
| Jatinder Dhaliwal Other companies: BioRestorative Therapies, Inc. (Director · Since at least Jun 10, 2026); LQR House Inc. (Director · Aug 21, 2023 – Oct 14, 2024 · Past) | Director · Jul 5, 2024 – Jul 5, 2024 · Past |
| Esha Randhawa Other companies: BioRestorative Therapies, Inc. (Director · Since at least Jul 13, 2026) | Director · Nov 19, 2024 – Nov 19, 2024 · Past |
| Vanila Singh Other companies: NMP Acquisition Corp. (Director · Since at least Jun 30, 2025) | Director · Jan 1, 2023 – Jan 29, 2024 · Past |
| Barbara Ruskin | Director · Mar 24, 2023 – Jan 29, 2024 · Past |
| Christopher Michael Chipman | Chief Financial Officer · Feb 16, 2021 – Jan 25, 2023 · Past |
| Jaydriane Panis | Director · Dec 17, 2024 – Dec 17, 2024 · Past |
| Jerrold Sendrow | Director · Feb 16, 2021 – Jan 29, 2024 · Past |
All 13 people
| Person | Seat |
|---|---|
| Judy Su | Director · Jul 5, 2024 – Jul 5, 2024 · Past |
| Michael F Dubin | Director · Jul 26, 2021 – Jan 29, 2024 · Past |
| Thani Jambulingam | Director · Jan 1, 2023 – Jan 29, 2024 · Past |
Log in to ask 6ix AI your own questions about Virpax Pharmaceuticals, Inc.